from Wlodarska et al., 2 who proposed a non-IgH FOXP1 translocation partner on chromosome 2q36 in one lymphoma, based on available cytogenetic data. Therefore, FOXP1 may exhibit a similar promiscuity with respect to its translocation partners, as has been reported for other genes (e.g. BCL6) that are frequently involved in translocations in B-cell lymphomas. In three cases (N2, 3 and 5) the FOXP1 breakpoints we mapped by interphase FISH to the 5 0 end of the FOXP1 gene as previously reported by Streubel et al.
1
Recent studies have identified a variable percentage of DLBCL with strong nuclear expression of the FOXP1 protein and, at least in some series, FOXP1 expression appears to be associated with poor survival among DLBCL patients. [5] [6] [7] However, molecular mechanisms that are involved in the regulation of FOXP1 expression are largely unknown. A gain of genomic material suggested by the presence of additional FISH signals (three or four) at the FOXP1 locus was found in 79 samples (29%) included in this study (30 DLBCL, 45 MZBL, three FL and one MCL, respectively; Figure 1f ). The percentages of cells carrying a gain varied from 10 to 95% in different samples. Using classical cytogenetic data and subsequent FISH analysis with a chromosome 3, a-satellite peri-centrometic probe (Abbott), we were able to further clarify this abnormality in 32 samples. Our data indicated the presence of trisomy 3 in the majority (75%) of samples with over-representation of the FOXP1 locus.
All evaluable samples (four of five) that harbored a chromosomal breakpoint in the FOXP1 locus showed strong nuclear FOXP1 protein expression patterns when stained with the JC12 monoclonal antibody (Figure 1e ). In addition, FOXP1 protein expression was evaluated in representative samples with and without over-representation of the FOXP1 locus. Nuclear expression in a varying proportion of the cells was detected in 38 out of 40 cases (95%) with a genomic gain/trisomy 3 ( Figure 1g ). However, FOXP1 protein expression was also observed in 19 out of 48 samples (40%) without evidence of genetic imbalances at this locus. Our results, together with published data 1, 2 indicate that genetic alterations at the 3p13 locus, which include chromosomal breakpoints or more frequently, genomic gains of the FOXP1 locus or trisomy 3, are associated with strong FOXP1 protein expression. Interestingly, a recent study of Bea et al. 8 reported genomic gains of chromosome 3 to be associated with the activated B-cell (ABC)-like DLBCL subtype and, therefore, as an adverse prognostic factor in DLBCL. It has to be noted, however, that a proportion of DLBCL without evidence of genetic aberrations of the FOXP1 locus or trisomy 3 shows similarly strong FOXP1 protein expression levels suggesting that mechanisms other than underlying genetic alterations can upregulate FOXP1 protein expression (e.g. as part of a physiological response of FOXP1 upon B-cell activation or by epigenetic mechanisms). Asparagine synthetase (ASY) is an enzyme that produces asparagine from aspartic acid in an ATP-dependent manner.
The ASY gene is conserved in mammalian cells; however, the expression of the gene is repressed in acute lymphoblastic leukemia (ALL) cells preventing them from synthesizing asparagine. 1 As ALL cells depend on extracellular sources of asparagine to survive, depletion of asparagine by L-asparaginase leads to cell death; therefore, the enzyme has been used for the Letters to the Editor treatment of childhood ALL. 2 Methylation of CpG islands of genes is one of the epigenetic mechanisms for silencing of genes, and aberrant methylation of CpG islands has been observed in a cohort of genes in tumor cells. Little is known about the methylation status of the ASY gene in ALL patients; here, we show that this gene is often methylated in ALL bone marrow samples.
The ASY gene has a CpG island located from À313 to þ 336 including 50 CpG sites. To estimate the methylation status of the CpG island, we utilized the restriction enzyme BstUI. The enzyme recognizes the CGCG sequence, and seven CGCG sites are in the CpG island. Only methylated cytosine in the CGCG is digested by BstUI after sodium bisulfate treatment, as it is not converted into uracil by treatment with sodium bisulfate; and thus, the CGCG sequence remains unchanged and is recognized by BstUI (Figure 1a) . We amplified the CpG island of the ASY gene by polymerase chain reaction (PCR) specific for bisulfate modified DNA, and the PCR product was digested with BstUI. As shown in Figure 1b , PCR product of B-lineage ALL bone marrow sample from patient no. 3 was not digested by BstUI; on the other hand, those of patient nos. 1 and 2 were digested by BstUI. After chemotherapy-induced remission, no PCR products were digested with BstUI ( Figure 1b) . To confirm the methylation, the PCR products were cloned into a plasmid vector, and three to six independent clones were sequenced. As expected, the sample at diagnosis for patient no. 3 that was not digested by BstUI was not methylated as determined by sequencing. In contrast, B-lineage ALL samples from patient nos. 1 and 2 at diagnosis, which were digested with BstUI, were methylated as shown by DNA sequencing (Figure 1c) . We expanded our analysis to 19 B-lineage ALL bone marrow samples at diagnosis and remission using sodium bisulfate conversion of genomic DNA, followed by BstUI digestion and sequencing analysis. A total of 14 of 19 (74%) B-lineage ALL bone marrow samples at diagnosis were methylated in the CpG island (Tables 1 and 2 ). After chemotherapeutic-induced remission, all of the bone marrow samples were unmethylated, including the 14 patients whose B-lineage ALL samples at diagnosis were methylated (Table 1) . Interestingly, five B-lineage ALL (26%) samples were not methylated (Tables 1 and 2 ); and thus, these patients might not benefit from L-asparaginase therapy. In addition, two B-lineage ALL samples (nos. 10 and 11), which were methylated at diagnosis, were re-methylated at relapse, and the other two samples (nos. 12 and 13), which were unmethylated at diagnosis, were unmethylated at relapse.
Next, we examined whether the ASY gene is methylated in T-cell acute lymphoblastic leukemia (T-ALL). Thirty-five of a total of 42 T-ALL samples (83%) were digested by BstUI and seven samples (17%) were undigested ( Figure 2a and Table 2 ). These results strongly suggested that the ASY gene in T-ALL is also methylated at a high frequency, consistent with T-ALL being sensitive to L-asparaginase therapy.
We also examined the methylation status of ASY gene in brain and breast tumors. Using five brain tumor samples, we analyzed the methylation status in the CpG island of ASY from À313 to þ 25 by sequencing. Most CpG sites in the gene were not methylated in brain tumors (Figure 2b) . In breast tumors, 11 samples were analyzed by BstUI digestion, and none were digested by BstUI (data not shown), suggesting that the gene is not methylated in breast tumors. Taken together, these results clearly show that the CpG island of the ASY gene is methylated in both B-lineage ALL and T-ALL, but not in brain and breast tumors.
A CpG island of the ASY gene has been reported to be methylated in the murine lymphoma cell line 6C3HED, as well as the human leukemia cell lines 1873 and 1929, and these cells do not express ASY; as a consequence, these cells are L-asparaginase sensitive. 3, 4 Studies of the leukemia cell line 1873 found that the lysine residues at position 9 (H3K9) and position 4 (H3K4) of histone H3 of ASY in the CpG island were deacetylated and demethylated, respectively. 5 These findings showed that suppression of expression of ASY occurs by multiple steps. Interestingly, however, sensitivity to L-asparaginase was thought not to be associated with the expression levels of ASY in ALL cells having the t(12; 21) chromosomal alteration. 6 Stams et al. 6 found that although these ALL cells expressed ASY mRNA, they were significantly more sensitive to L-asparaginase than ALL cells not having the translocation. On the other hand, the same investigators found that levels of expression of ASY mRNA in TEL-AML1-negative ALL cells were correlated with their L-asparaginase resistance. 7 Krejci et al. 8 also showed higher expression of ASY mRNA in TEL-AML1-positive Abbreviations: ALL, acute lymphoblastic leukemia; ASY, asparagine synthetase; T-ALL, T-cell acute lymphoblastic leukemia. A total of 19 B-lineage ALL and 42 T-ALL bone marrow samples were analyzed for their methylation status of ASY gene, and methylation status is shown as a percent of the total samples.
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ALL cells after L-asparaginase treatment. The relationship between methylation of the ASY promoter and chromosomal translocation remains to be determined.
In summary, we show a correlation between methylation and ALL, and our data for the first time demonstrate that the ASY gene is often methylated in ALL cells, thus explaining why ALL Strategy of methylation analysis of asparagine synthetase (ASY) in acute lymphoblastic leukemia (ALL). (a) The CGCG is the target sequence of the BstUI restriction enzyme. Treatment with sodium bisulfate leads to conversion of cytosine into uracil. Methyl-cytosine is not converted, and the CGCG is recognized by BstUI; therefore, only the methylated CpG island is digested by BstUI. (b) Genomic DNA was modified by sodium bisulfate using EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA). The CpG island of ASY gene (À313 to þ 336, transcription initiation site was considered as þ 1 as described previously 4 ) was amplified from the modified genomic DNA as a template using specific primers (sense primer: Letters to the Editor cells may be sensitive to L-asparaginase. These studies contribute to the understanding of the regulation of ASY in ALL, and suggest that a simple restriction enzyme test might predict who will respond to L-asparaginase. Methylation status of asparagine synthetase (ASY) in other tumor cells. (a) The CpG island of ASY was amplified by bisulfate modified DNA-specific PCR using T-cell acute lymphoblastic leukemia (T-ALL) genomic DNA, and the PCR products were digested with BstUI and separated by agarose gel electrophoresis. (b) The CpG island of ASY from À313 to þ 25 was amplified by PCR specific for bisulfate modified DNA using brain tumor genomic DNA, and the PCR products were sequenced. Methylated and unmethylated cytosines are shown by closed and open squares, respectively.
